Changes in intraocular pressure associated with topical dorzolamide and oral methazolamide in glaucomatous dogs

Veterinary Ophthalmology

Volumn 4, Issue 1, 2001, Pages 61-67

  Gelatt, Kirk N ^a   MacKay, Edward O ^a  

^a University of Florida College of Veterinary Medicine   (United States)

Author keywords

Carbonic anhydrase inhibitors; Dogs; Dorzolamide; Glaucoma; Methazolamide

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

ANTIHYPERTENSIVE AGENT; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; EYE DROPS; METHAZOLAMIDE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; ORAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; METHAZOLAMIDE; OPHTHALMIC SOLUTIONS; SULFONAMIDES; THIOPHENES; TREATMENT OUTCOME;

EID: 0035292268     PISSN: 14635216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-5224.2001.00141.x     Document Type: Article

References (23)

1. Becker B. Use of methazolamide (Neptazane) in the therapy of glaucoma. American Journal of Ophthalmology 1960; 49: 1307-1311.
2. Maren TH, Haywood JR, Chapman SK, Zimmerman TJ. The pharmacology of methazolamide in relation to the treatment of glaucoma. Investigative Ophthalmology and Visual Science 1977; 16: 730-742.
3. Gelatt KN, Brooks DE. The canine glaucomas. In: Veterinary Ophthalmology, 3rd edn. (ed. Gelatt KN) Lippincott/Williams & Wilkins, Baltimore, 1999; 701-754.
4. Maren TH, Conroy CW, Wynns GC et al. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. Journal of Ocular Pharmacology and Therapeutics 1997; 13: 23-30.
5. Pfeiffer N. Dorzolamide: Development and clinical application of a topical carbonic anhydrase inhibitor. Survey of Ophthalmology 1997; 42: 137-151.
6. Lippa EA, Carlson LE, Ehinger LO et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Archives of Ophthalmology 1992; 110: 495-499.
7. Gelatt KN, Gum GG, Williams LW et al. Ocular hypotensive effects of carbonic anhydrase inhibitors in normotensive and glaucomatous Beagles. American Journal of Veterinary Research 1979; 40: 334-345.
8. Pickett JP, Champagne ES. Effects of chronic administration of an oral carbonic anhydrase inhibitor (dichlorphenamide) on intraocular pressure and serum potassium levels in the normal canine. Proceedings of the American College of Veterinary Ophthalmologists 1993; 24: 125126.
9. Haskins SC, Munger RJ, Helphrey MG et al. Effect of acetazolamide on blood acid-base and electrolyte values in dogs. Journal of the American Veterinary Medical Association 1981; 179: 792-796.
10. Hamlin RL, Smith RC, Powers TE et al. Efficacy of various diuretics in normal dogs. Journal of the American Veterinary Medical Association 1965; 146: 1417-1420.
11. Starita RJ, Piltz-Seymour JR, Fellman RL. Ocular and systemic side effects of carbonic anhydrase inhibitors. In: Complications of Glaucoma Therapy, (eds Sherwood MB, Spaeth GL) Slack Incorporated, Thorofare, New Jersey, 1990; 57-76.
12. Sugrue MF. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. Journal of Ocular Pharmacology and Therapeutics 1966; 12: 363-376.
13. Wang RF, Serle JB, Podos SM et al. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Archives of Ophthalmology 1991; 109: 1297-1299.
14. Brechue WF, Maren TH. A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion. Experimental Eye Research 1993; 57: 67-78.
15. Fanous MM, Challa P, Maren TH. Comparison of intraocular pressure lowering by topical and systemic carbonic anhydrase inhibitors in the rabbit. Journal of Ocular Pharmacology and Therapeutics 1999; 15: 51-57.
16. King TC, Gum GG, Gelatt KN. Evaluation of a topical carbonic anhydrase inhibitor (MK-927) in normo tensive and glaucomatous dogs. Proceedings of the American College of Veterinary Ophthalmologists 1990; 21: 175-176.
17. King TC, Gum GG, Gelatt KN. Evaluation of a topically administered carbonic anhydrase inhibitor (MK-927) in normotensive and glaucomatous Beagles. American Journal of Veterinary Research 1991; 52: 2067-2070.
18. SAS/STAT Guide for Personal Computers, Version 6ed. SAS Institute, Inc., Gary, NC, 1991.
19. Centofanti M, Manni GL, Napoli D, Bucci MG. Comparative effects of intraocular pressure between systemic and topical carbonic anhydrase inhibitors: a clinical masked, cross-over study. Pharmacology Research 1997; 35: 481-485.
20. Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Archives of Ophthalmology 1997; 115: 45-49.
21. Rosenberg LF, Krupin T, Tang LQ, Hong PH, Ruderman JM. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology 1998; 105: 92-93.
22. Larsson LI, Alm A. Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide. Archives of Ophthalmology 1998; 116: 19-24.
23. Hutzelmann JE, Polis AB, Michael AJ et al. A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Oral to topical CAI study group. Acta Ophthalmologica Scandinavia 1998; 76: 717-722.